Results 141 to 150 of about 6,359 (194)

Targeting neutrophil extracellular traps: an emerging strategy for improving the management of refractory asthma. [PDF]

Front Med (Lausanne)
Wang XH, Song MZ, Li M.
europepmc   +1 more source

Glycosaminoglycans activate peptidylarginine deiminase 4 by enhancing calcium affinity. [PDF]

Proc Natl Acad Sci U S A
Bereta GP, Bielecka E, Marzec K, Pijanowski Ł, Biela AP, Wilk P, Kamińska M, Nowak J, Wątor-Wilk E, Grudnik P, Kowalczyk D, Kozieł J, Mydel P, Poręba M, Kantyka T.   +14 more
europepmc   +1 more source

Context-dependent contribution of peptidyl arginine deiminase 4 (PAD4) to neutrophil extracellular trap formation and liver injury in acute and chronic hepatotoxicant challenge. [PDF]

Toxicol Sci
Capece GE, Patel AK, Hu D, Roychowdhury T, Hazel B, Kothapalli J, Mac NA, Denorme F, Campbell RA, Poole LG.   +9 more
europepmc   +1 more source

DUSP6 promotes motility, invasion, and tumorigenicity of thyroid cancer cells via IL8-induced neutrophil extracellular traps. [PDF]

Sci Rep
Xiao W, Luo L, Yang Y, Chen W, Yang C.
europepmc   +1 more source

Neutrophil Extracellular Traps in Diabetic Kidney Disease: Mechanisms of Pathogenesis and Emerging Therapeutic Strategies. [PDF]

Drug Des Devel Ther
Wang B, Zhang R, Liu X, Shang Y, Jin T, Gao C, Yang N, Jin J, He Q.   +8 more
europepmc   +1 more source

PAD4 takes charge during neutrophil activation: Impact of PAD4 mediated NET formation on immune‐mediated disease

Journal of Thrombosis and Haemostasis, 2021
Peptidyl arginine deiminase 4 (PAD4) is an enzyme that converts arginine into citrulline. PAD4 is expressed in neutrophils that, when activated, can drive the formation of neutrophil extracellular traps (NETs). Uncontrolled activation of PAD4 and subsequent citrullination of proteins is increasingly recognized as a driver of (auto)immune diseases ...
Chris Reutelingsperger, Gerry Nicolaes, Kanin Wichapong   +2 more
exaly   +5 more sources

Some of the next articles are maybe not open access.

Related searches:

Autoantibodies to PAD4 and BRAF in rheumatoid arthritis

Autoimmunity Reviews, 2012
Rheumatoid arthritis (RA) is a chronic autoimmune disease that causes cartilage and bone destruction. The mechanisms leading to RA are unknown. There is currently no reliable cure for RA. Early treatment can reduce inflammation, joint damage and bone destruction. Thus, early diagnosis of RA is critical.
Jean Roudier, Isabelle Auger, Nathalie Balandraud   +2 more
exaly   +4 more sources

Prevalence of soluble peptidylarginine deiminase 4 (PAD4) and anti-PAD4 antibodies in autoimmune diseases

Clinical Rheumatology, 2015
The objectives of this study are to investigate the prevalence of PAD4 and anti-PAD4 antibodies (Abs) in autoimmune diseases and to clarify their association with anticitrullinated protein antibodies (ACPAs) and shared epitope (SE) in patients with rheumatoid arthritis (RA).
Naoto, Umeda, Isao, Matsumoto, Hoshimi, Kawaguchi, Yuko, Kurashima, Yuya, Kondo, Hiroto, Tsuboi, Hiroshi, Ogishima, Takeshi, Suzuki, Yayoi, Kagami, Takuya, Sakyu, Akihito, Ishigami, Naoki, Maruyama, Takayuki, Sumida   +12 more
openaire   +2 more sources

Two novel sandwich ELISAs identify PAD4 levels and PAD4 autoantibodies in patients with rheumatoid arthritis

Modern Rheumatology, 2012
The peptidylarginine deiminase 4 (PAD4) gene and PAD4 autoantibodies have been associated with rheumatoid arthritis (RA) and its pathogenesis. Therefore, methods for accurately determining their levels in the peripheral blood of these patients would be a diagnostic asset.
Akihito, Ishigami, Yoshiaki, Uchida, Tsuyoshi, Miyazaki, Setsuko, Handa, Eun-Kyoung, Choi, Yong-Sun, Kim, Yasushi, Kasahara, Naoki, Maruyama   +7 more
openaire   +2 more sources

Novel Peptidylarginine Deiminase Type 4 (PAD4) Inhibitors

ACS Medicinal Chemistry Letters, 2022
Provided herein are novel compounds as peptidylarginine deiminase type 4 (PAD4) inhibitors, pharmaceutical compositions, use of such compounds in treating diseases, and processes for preparing such compounds.
openaire   +2 more sources